Search

Trata-se de estudo de corte transversal, realizado mediante a aplicação de questionário em uma amostra aleatória e representativa de 489 agentes comunitários de saúde (ACS) a respeito da tuberculose (TB), suas medidas de controle e o tratamento diretamente observado (TDO), em Belo Horizonte, Minas Gerais, Brasil. A proporção média de itens acertados foi de 74,6%. A proporção média de acertos no domínio TB foi 81%; no domínio medidas de controle, 84,1%; e sobre TDO, 59,4%. Verificou-se uma lacuna no conhecimento sobre a identificação de pacientes com TB pulmonar, o público-alvo do TDO, e a técnica adequada para supervisão do tratamento. Foi observada associação entre maior conhecimento e tempo de atuação igual ou superior a três anos (RC = 2,3) e acompanhamento de casos nos 12 meses anteriores à entrevista (RC = 1,7). Este trabalho apresentou informações inéditas na literatura científica sobre o nível de conhecimento dos ACS sobre TDO, e poderá subsidiar estratégias destinadas ao aperfeiçoamento das atividades de controle da tuberculose.

Abstract: This study sought to develop and evaluate a new patient-reported outcome measure to assess perceived barriers to antiretroviral therapy (ART) adherence. The Perceived Barriers to Antiretroviral Therapy Adherence (PEDIA) scale was developed based on individual interviews with patients. After pilot testing and assessing the evidence based on content analysis, the scale’s revisions resulted in a 40-item version. The PEDIA was applied to 415 HIV-infected adults receiving ART for a maximum of 180 days, recruited from three healthcare facilities of reference in the city of Belo Horizonte, Minas Gerais State, Brazil. The analyses included exploratory factor analysis, internal consistency, item response theory, temporal stability, and predictive test-criterion relationship. The scale’s final version contains 18 items distributed in three dimensions, as follows: cognitive and routine problems (4 items); medication and health concerns (6 items); and patient’s fears and feelings (8 items). The results of McDonald’s omega and temporal stability demonstrate that the PEDIA is internally consistent and yields stable scores over time. The assessment of the information’s functions suggested that the three dimensions were informative for assessing a broad range of latent traits. Evidence concerning the test-criterion relationship confirmed that the PEDIA was able to predict non-adherence three months later. Our findings suggest that the PEDIA is a psychometrically adequate tool for evaluating perceived barriers in adult patients initiating ART. It could be used in both research and clinical practice for the early detection of patients at risk of non-adherence and for the identification of potentially modifiable barriers.

Abstract: We evaluated adherence to highly active antiretroviral therapy (HAART) and its associated factors according to the type of regimen in patients initiating treatment in Belo Horizonte, Minas Gerais State, Brazil. We measured adherence using the eight items Morisky Therapeutic Adhesion Scale (MMAS-8) and compared the use of “backbone” tenofovir/lamivudine plus efavirenz one tablet once-daily (STR) or dolutegravir in multi-tablet once-daily (MTR-DTG), or other multi-tablet regimens (MTR-other). We conducted a multivariate logistic regression analysis to address factors associated with adherence. A total of 393 patients were included, 254 used STR, 106 MTR-DTG, and 33 MTR-other. The overall adhesion rate was 44.8% (95%CI: 39.4; 50.1), 50% for MTR-DTG, 43.3% for STR and 39.4% for MTR-other. Multivariate analysis showed a higher chance of adherence among patients using MTR-DTG, those who received and understood counseling about their treatment and with a higher quality of life. Prior use of illicit drugs in the lifetime was associated with poorer adherence. Overall adherence was low, highlighting the need for strategies focusing on counseling about medicines and substance use. Pill burden was not an issue for patients using MTR-DTG once-daily, who achieved better results.